(Q34403098)

English

EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial (English)

1 reference

Europe PubMed Central

1 August 2017

phase II clinical trial

0 references

0 references

Robert H Dworkin

2

object named as

Robert H Dworkin

1 reference

Europe PubMed Central

1 August 2017

8

object named as

Gary Cutter

0 references

author name string

Andrew S C Rice

1

1 reference

Europe PubMed Central

1 August 2017

Tom D McCarthy

3

1 reference

Europe PubMed Central

1 August 2017

Praveen Anand

4

1 reference

Europe PubMed Central

1 August 2017

Chas Bountra

5

1 reference

Europe PubMed Central

1 August 2017

Philip I McCloud

6

1 reference

Europe PubMed Central

1 August 2017

Julie Hill

7

1 reference

Europe PubMed Central

1 August 2017

Geoff Kitson

9

1 reference

Europe PubMed Central

1 August 2017

Nuket Desem

10

1 reference

Europe PubMed Central

1 August 2017

Milton Raff

11

1 reference

Europe PubMed Central

1 August 2017

EMA401-003 study group

12

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

5 February 2014

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

383

1 reference

Europe PubMed Central

1 August 2017

9929

1 reference

Europe PubMed Central

1 August 2017

1637-1647

1 reference

Europe PubMed Central

1 August 2017

A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A small molecule angiotensin II type 2 receptor (AT₂R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II receptor type 2 activation is required for cutaneous sensory hyperinnervation and hypersensitivity in a rat hind paw model of inflammatory pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A new definition of neuropathic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A study of shingles and the development of postherpetic neuralgia in East London

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of psychological and physical function in neuropathic pain and nociceptive pain: implications for cognitive behavioral pain management programs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The evidence for pharmacological treatment of neuropathic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Analgesic therapy in postherpetic neuralgia: a quantitative systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The development and testing of the depression, anxiety, and positive outlook scale (DAPOS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Factor structure, reliability, and validity of the Pain Catastrophizing Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II type 2 receptor agonists--where should they be applied?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Expect analgesic failure; pursue analgesic success

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Topical capsaicin (high concentration) for chronic neuropathic pain in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiepileptic drugs for neuropathic pain and fibromyalgia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962337-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)62337-5

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34403098&oldid=1576631190"